Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle
Marc Kennis, March 1, 2022
Cyclopharm
Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.
CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!
[pdf-embedder url=”https://stocksdownunder.com/wp-content/uploads/securepdfs/2022/03/Stocks-Down-Under-Special-Report-on-Cyclopharm-1-March-2022.pdf” title=”Stocks Down Under Special Report on Cyclopharm – 1 March 2022″]
Stay up-to-date on ASX-listed Life Sciences stocks!
Make sure you subscribe to Stocks Down Under today
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Your invitation to the Freelancer Investor Day
Your invitation to the Freelancer Investor Day Freelancer (ASX: FLN) is a Sydney-based company that has been the subject of…
Kamala Harris stocks: If Joe Biden’s VP wins the White House in 2024, which stocks will win?
With the US Presidential election now certain to be a Kamala Harris v Donald Trump showdown, we’ve looked at so-called…
South32 (ASX:S32): Is it the dark horse amongst ASX 200 miners or have cyclones and commodity prices hit it too hard?
South32 (ASX:S32) began life as a spinoff from BHP back in 2015, capitalised at $9bn. In mid-2024, it is capped…